Dawang的个人主页 - 老虎社区

Dawang

Dawang

暂无个人介绍

IP属地：未知

623关注

136粉丝

0主题

0勋章

2021-09-13

New phone, new catalyst. Forget abt the lawsuit with Epic

抱歉，原内容已删除

2021-08-10

1 dosage 100 mcg versus 30mcg from pfizer

Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠疫苗可能比辉瑞更好对抗德尔塔变异毒株；突破性案例随着时间的推移而增加</blockquote>

2021-08-10

Hakuna Matata

Crude Oil and Iron Ore Prices in Tailspin as Covid Continues Spreading<blockquote>随着新冠疫情持续蔓延，原油和铁矿石价格陷入混乱</blockquote>

2021-09-07

Next milestone set, probably a question of not "if" but "when" (",)

抱歉，原内容已删除

2021-12-01

All this positive news, but unable to obtain that most elusive license.... so ironic.. 😂😂😂

抱歉，原内容已删除

2021-11-29

Electric Dreams!! 🎶🎶🎵

EV stocks surged in morning trading<blockquote>电动汽车股早盘飙升</blockquote>

2021-11-14

Showing the way to beat the virus 🙏✌👍🍯

Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>

2021-09-04

Not a Major threat (yet), but do stay alert of the unknowns

抱歉，原内容已删除

2021-07-29

The connection to the IOT and electrification of road Infra and EV (cars to talk to one another, on traffic jams etc) means chips' demand will only increase than decrease!

抱歉，原内容已删除

2021-07-10

At a crossroad for Tesla in PRC

Tesla Shares Form Death Cross, Portending Further Declines<blockquote>特斯拉股价形成死亡交叉，预示着进一步下跌</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3579482809178950","uuid":"3579482809178950","gmtCreate":1616389577709,"gmtModify":1623118706456,"name":"Dawang","pinyin":"dawang","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":136,"headSize":623,"tweetSize":208,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.19","exceedPercentage":"80.22%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.05","exceedPercentage":"81.00%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":692086334,"gmtCreate":1640791996458,"gmtModify":1640791997956,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Good buy or goodbye?&nbsp;","listText":"Good buy or goodbye?&nbsp;","text":"Good buy or goodbye?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/692086334","repostId":"2195501154","repostType":4,"isVote":1,"tweetType":1,"viewCount":3438,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696656222,"gmtCreate":1640689216110,"gmtModify":1640689217502,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Midas touches 👉🪙","listText":"Midas touches 👉🪙","text":"Midas touches 👉🪙","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696656222","repostId":"1128880653","repostType":4,"isVote":1,"tweetType":1,"viewCount":2951,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696358297,"gmtCreate":1640624615470,"gmtModify":1640624616773,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Tech propels the world economies!","listText":"Tech propels the world economies!","text":"Tech propels the world economies!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696358297","repostId":"2194109174","repostType":4,"isVote":1,"tweetType":1,"viewCount":3451,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696358899,"gmtCreate":1640624516339,"gmtModify":1640624554963,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Cure for mankind!","listText":"Cure for mankind!","text":"Cure for mankind!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696358899","repostId":"1175107411","repostType":4,"isVote":1,"tweetType":1,"viewCount":2873,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693763461,"gmtCreate":1640081786371,"gmtModify":1640081787683,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"New partnership, new growth, new opportunities. Kachng! 💰💰💰","listText":"New partnership, new growth, new opportunities. Kachng! 💰💰💰","text":"New partnership, new growth, new opportunities. Kachng! 💰💰💰","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693763461","repostId":"1129749044","repostType":4,"repost":{"id":"1129749044","kind":"news","pubTimestamp":1640052616,"share":"https://www.laohu8.com/m/news/1129749044?lang=zh_CN&edition=full","pubTime":"2021-12-21 10:10","market":"us","language":"en","title":"PLTR Stock Alert: 5 Things to Know About Palantir’s Latest Partnership<blockquote>PLTR股票提醒：关于Palantir最新合作伙伴关系需要了解的5件事</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129749044","media":"InvestorPlace","summary":"Despite announcing a new multi-year partnership with Dewpoint Therapeutics, shares of Palantir Techn","content":"<p><div> Despite announcing a new multi-year partnership with Dewpoint Therapeutics, shares of Palantir Technologies(NYSE:PLTR) are down more than 4% on the day. The weakness in PLTR stock can be attributed to...</p><p><blockquote><div>尽管宣布与Dewpoint Therapeutics建立新的多年合作伙伴关系，Palantir Technologies（纽约证券交易所股票代码：PLTR）的股价当天仍下跌超过4%。PLTR股票的疲软可归因于...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/pltr-stock-alert-5-things-to-know-about-palantirs-latest-partnership/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/pltr-stock-alert-5-things-to-know-about-palantirs-latest-partnership/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PLTR Stock Alert: 5 Things to Know About Palantir’s Latest Partnership<blockquote>PLTR股票提醒：关于Palantir最新合作伙伴关系需要了解的5件事</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPLTR Stock Alert: 5 Things to Know About Palantir’s Latest Partnership<blockquote>PLTR股票提醒：关于Palantir最新合作伙伴关系需要了解的5件事</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-21 10:10</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Despite announcing a new multi-year partnership with Dewpoint Therapeutics, shares of Palantir Technologies(NYSE:PLTR) are down more than 4% on the day. The weakness in PLTR stock can be attributed to...</p><p><blockquote><div>尽管宣布与Dewpoint Therapeutics建立新的多年合作伙伴关系，Palantir Technologies（纽约证券交易所股票代码：PLTR）的股价当天仍下跌超过4%。PLTR股票的疲软可归因于...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/pltr-stock-alert-5-things-to-know-about-palantirs-latest-partnership/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/pltr-stock-alert-5-things-to-know-about-palantirs-latest-partnership/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/12/pltr-stock-alert-5-things-to-know-about-palantirs-latest-partnership/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2021/12/pltr-stock-alert-5-things-to-know-about-palantirs-latest-partnership/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129749044","content_text":"Despite announcing a new multi-year partnership with Dewpoint Therapeutics, shares of Palantir Technologies(NYSE:PLTR) are down more than 4% on the day. The weakness in PLTR stock can be attributed to general market weakness, as the S&P 500 and Nasdaq are both down today. However, let’s dive into the details on the new partnership that has shareholders of PLTR stock excited.\nThe partnership will see Dewpoint utilize Palantir’s Foundry platform to further research and understand condensates biology. The Foundry platform will help researchers analyze lab data and other data sources. Researchers at Dewpoint will also use Foundry to store their centralized knowledge repository. Additionally, they will use it to contextualize test results and prioritize the best possible outcome.\nLalarukh Haris Shaikh, Palantir’s head of biotech, praised the partnership. She commented:\n\n “We think Dewpoint is changing the way the world approaches drug design by exploring new frontiers of disease biology, requiring a game changing solution that goes beyond just cloud and infrastructure to drive their R&D and scale with their vision as they grow. We are proud to partner with Dewpoint and share their passion of working on one of the most exciting translational medicine approaches of our time.”\n\nPLTR Stock: What to Know About the Dewpoint Partnership\n\nDewpoint is a leading research company that seeks to understand the nature of condensates in order to develop drugs. Condensates are involved in many serious diseases, such as cancer, metabolic disease and other rare genetic disorders.\nThe Foundry platform is designed to integrate siloed information sources that will lead to data-driven analysis and conclusions. Foundry will be able to “work seamlessly” with the existing Dewpoint systems.\nFor example, the expansion of Dewpoint’s data foundation to include “advanced genetic analysis for disease association and correlation with condensate content” will help the company discover potential medical breakthroughs.\nDewpoint CEO Ameet Nathwani is looking forward to the prospects that Foundry can bring to the company. He stated that, “Key to our approach has been creating a seamless connection between our wet-lab and dry-lab capabilities, with machine learning and AI at the center. Foundry has provided us with a solid foundation for us to fully connect and operationalize our entire lab to enterprise and enable the discovery and development of new drugs.”\nThis partnership comes after Palantir announced that they had won a second option year with the U.S. Army. Indeed, that deal is worth $116.3 million.","news_type":1,"symbols_score_info":{"PLTR":0.9}},"isVote":1,"tweetType":1,"viewCount":3206,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693647332,"gmtCreate":1640017883672,"gmtModify":1640017885097,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"ARK running off liaoz","listText":"ARK running off liaoz","text":"ARK running off liaoz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693647332","repostId":"1191022113","repostType":2,"repost":{"id":"1191022113","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1639626011,"share":"https://www.laohu8.com/m/news/1191022113?lang=zh_CN&edition=full","pubTime":"2021-12-16 11:40","market":"us","language":"en","title":"Cathie Wood Sells Another $88M In Tesla Day After Piling Up Stake In Chinese EV Rival<blockquote>凯西·伍德(Cathie Wood)在增持中国电动汽车竞争对手股份后，在特斯拉日又出售了8800万美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1191022113","media":"Benzinga","summary":"Cathie Wood-led Ark Invest on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — i","content":"<p><b>Cathie Wood</b>-led&nbsp;<b>Ark Invest</b>&nbsp;on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — in&nbsp;<b>Tesla Inc</b>, booking profit in the stock as it rose after days of losses.</p><p><blockquote><b>凯西·伍德</b>-led<b>方舟投资</b>周三出售了90,455股股票，估计价值8830万美元<b>特斯拉公司</b>，该股在连续几天下跌后上涨时获利了结。</blockquote></p><p> The stock pared earlier losses to close&nbsp;1.82% higher at $975.99 a share on Wednesday. The Elon Musk-led company’s shares are up about 34% so far this year and down about 7.5% over the past month.</p><p><blockquote>该股周三收高1.82%，收于每股975.99美元。这家埃隆·马斯克(Elon Musk)领导的公司股价今年迄今上涨了约34%，过去一个月下跌了约7.5%。</blockquote></p><p> Ark Invest sold the shares via the&nbsp;<b>Ark Innovation ETF</b>(BATS:ARKK), the&nbsp;<b>Ark Autonomous Technology &amp; Robotics ETF</b>(BATS:ARKQ) and the&nbsp;<b>Ark Next Generation Internet ETF</b>(BATS:ARKW)&nbsp;on Wednesday.</p><p><blockquote>Ark Invest通过<b>方舟创新ETF</b>（蝙蝠：ARKK），<b>Ark自主技术与机器人ETF</b>（蝙蝠：ARKQ）和<b>方舟下一代互联网ETF</b>（蝙蝠：ARKW）周三。</blockquote></p><p> Tesla’s weight in ARKK and ARKW had already slipped below the 10% threshold at 8.14% and 9.35%, respectively, ahead of Wednesday’s trade. In ARKQ, it constituted 10.59% of the portfolio.</p><p><blockquote>在周三交易之前，特斯拉在ARKK和ARKW的权重已经跌破10%的门槛，分别为8.14%和9.35%。在ARKQ中，它占投资组合的10.59%。</blockquote></p><p> The three ETFs held 1.99 million shares — worth $1.91 billion — in Tesla, ahead of Wednesday’s trade.</p><p><blockquote>在周三交易之前，这三只ETF持有特斯拉199万股股票，价值19.1亿美元。</blockquote></p><p> Ark Invest has been booking profit in Tesla since September — selling over $3 billion worth of shares — after years of piling up shares in the electric vehicle company at far lower levels.</p><p><blockquote>Ark Invest自9月份以来一直在特斯拉获利，出售了价值超过30亿美元的股票，此前多年来一直在这家电动汽车公司的股票处于低得多的水平。</blockquote></p><p> Tesla continues to be the firm's biggest bet across ETFs — a stock it predicts would hit the&nbsp;$3,000 mark by the end of 2025.</p><p><blockquote>特斯拉仍然是该公司在ETF中最大的押注——预计该股到2025年底将触及3,000美元大关。</blockquote></p><p> Wood favors the automotive industry’s switch to electric vehicles and earlier thismonth started buying sharesin the U.S. listed Chinese electric automaker&nbsp;<b>Xpeng Inc</b>.</p><p><blockquote>伍德支持汽车行业转向电动汽车，并于本月早些时候开始购买这家在美国上市的中国电动汽车制造商的股票<b>小鹏汽车</b>.</blockquote></p><p> Here are the other key trades on Wednesday:</p><p><blockquote>以下是周三的其他关键交易：</blockquote></p><p> <ul>  <li>Bought 104,489 shares — estimated to be worth $21.3 million — in&nbsp;<b>Roku Inc</b>&nbsp;on the dip. The stock closed 7.95% lower at $203.94 a share on Wednesday.</li>  <li>Bought 705,660 shares — estimated to be worth $13.7 million — in&nbsp;<b>Robinhood Markets Inc</b>. The stock closed 1.93% higher at $19.50 a share.</li> </ul></p><p><blockquote><ul><li>购买了104,489股股票，估计价值2,130万美元<b>Roku公司</b>在下降。该股周三收盘下跌7.95%，至每股203.94美元。</li><li>购买了705,660股股票，估计价值1,370万美元<b>罗宾汉市场公司</b>该股收涨1.93%，报每股19.50美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Sells Another $88M In Tesla Day After Piling Up Stake In Chinese EV Rival<blockquote>凯西·伍德(Cathie Wood)在增持中国电动汽车竞争对手股份后，在特斯拉日又出售了8800万美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Sells Another $88M In Tesla Day After Piling Up Stake In Chinese EV Rival<blockquote>凯西·伍德(Cathie Wood)在增持中国电动汽车竞争对手股份后，在特斯拉日又出售了8800万美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-16 11:40</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Cathie Wood</b>-led&nbsp;<b>Ark Invest</b>&nbsp;on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — in&nbsp;<b>Tesla Inc</b>, booking profit in the stock as it rose after days of losses.</p><p><blockquote><b>凯西·伍德</b>-led<b>方舟投资</b>周三出售了90,455股股票，估计价值8830万美元<b>特斯拉公司</b>，该股在连续几天下跌后上涨时获利了结。</blockquote></p><p> The stock pared earlier losses to close&nbsp;1.82% higher at $975.99 a share on Wednesday. The Elon Musk-led company’s shares are up about 34% so far this year and down about 7.5% over the past month.</p><p><blockquote>该股周三收高1.82%，收于每股975.99美元。这家埃隆·马斯克(Elon Musk)领导的公司股价今年迄今上涨了约34%，过去一个月下跌了约7.5%。</blockquote></p><p> Ark Invest sold the shares via the&nbsp;<b>Ark Innovation ETF</b>(BATS:ARKK), the&nbsp;<b>Ark Autonomous Technology &amp; Robotics ETF</b>(BATS:ARKQ) and the&nbsp;<b>Ark Next Generation Internet ETF</b>(BATS:ARKW)&nbsp;on Wednesday.</p><p><blockquote>Ark Invest通过<b>方舟创新ETF</b>（蝙蝠：ARKK），<b>Ark自主技术与机器人ETF</b>（蝙蝠：ARKQ）和<b>方舟下一代互联网ETF</b>（蝙蝠：ARKW）周三。</blockquote></p><p> Tesla’s weight in ARKK and ARKW had already slipped below the 10% threshold at 8.14% and 9.35%, respectively, ahead of Wednesday’s trade. In ARKQ, it constituted 10.59% of the portfolio.</p><p><blockquote>在周三交易之前，特斯拉在ARKK和ARKW的权重已经跌破10%的门槛，分别为8.14%和9.35%。在ARKQ中，它占投资组合的10.59%。</blockquote></p><p> The three ETFs held 1.99 million shares — worth $1.91 billion — in Tesla, ahead of Wednesday’s trade.</p><p><blockquote>在周三交易之前，这三只ETF持有特斯拉199万股股票，价值19.1亿美元。</blockquote></p><p> Ark Invest has been booking profit in Tesla since September — selling over $3 billion worth of shares — after years of piling up shares in the electric vehicle company at far lower levels.</p><p><blockquote>Ark Invest自9月份以来一直在特斯拉获利，出售了价值超过30亿美元的股票，此前多年来一直在这家电动汽车公司的股票处于低得多的水平。</blockquote></p><p> Tesla continues to be the firm's biggest bet across ETFs — a stock it predicts would hit the&nbsp;$3,000 mark by the end of 2025.</p><p><blockquote>特斯拉仍然是该公司在ETF中最大的押注——预计该股到2025年底将触及3,000美元大关。</blockquote></p><p> Wood favors the automotive industry’s switch to electric vehicles and earlier thismonth started buying sharesin the U.S. listed Chinese electric automaker&nbsp;<b>Xpeng Inc</b>.</p><p><blockquote>伍德支持汽车行业转向电动汽车，并于本月早些时候开始购买这家在美国上市的中国电动汽车制造商的股票<b>小鹏汽车</b>.</blockquote></p><p> Here are the other key trades on Wednesday:</p><p><blockquote>以下是周三的其他关键交易：</blockquote></p><p> <ul>  <li>Bought 104,489 shares — estimated to be worth $21.3 million — in&nbsp;<b>Roku Inc</b>&nbsp;on the dip. The stock closed 7.95% lower at $203.94 a share on Wednesday.</li>  <li>Bought 705,660 shares — estimated to be worth $13.7 million — in&nbsp;<b>Robinhood Markets Inc</b>. The stock closed 1.93% higher at $19.50 a share.</li> </ul></p><p><blockquote><ul><li>购买了104,489股股票，估计价值2,130万美元<b>Roku公司</b>在下降。该股周三收盘下跌7.95%，至每股203.94美元。</li><li>购买了705,660股股票，估计价值1,370万美元<b>罗宾汉市场公司</b>该股收涨1.93%，报每股19.50美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ROKU":"Roku Inc","ARKK":"ARK Innovation ETF","ARKW":"ARK Next Generation Internet ETF","HOOD":"Robinhood","TSLA":"特斯拉","XPEV":"小鹏汽车","ARKQ":"ARK Autonomous Technology & Robotics ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191022113","content_text":"Cathie Wood-led Ark Invest on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — in Tesla Inc, booking profit in the stock as it rose after days of losses.\nThe stock pared earlier losses to close 1.82% higher at $975.99 a share on Wednesday. The Elon Musk-led company’s shares are up about 34% so far this year and down about 7.5% over the past month.\nArk Invest sold the shares via the Ark Innovation ETF(BATS:ARKK), the Ark Autonomous Technology & Robotics ETF(BATS:ARKQ) and the Ark Next Generation Internet ETF(BATS:ARKW) on Wednesday.\nTesla’s weight in ARKK and ARKW had already slipped below the 10% threshold at 8.14% and 9.35%, respectively, ahead of Wednesday’s trade. In ARKQ, it constituted 10.59% of the portfolio.\nThe three ETFs held 1.99 million shares — worth $1.91 billion — in Tesla, ahead of Wednesday’s trade.\nArk Invest has been booking profit in Tesla since September — selling over $3 billion worth of shares — after years of piling up shares in the electric vehicle company at far lower levels.\nTesla continues to be the firm's biggest bet across ETFs — a stock it predicts would hit the $3,000 mark by the end of 2025.\nWood favors the automotive industry’s switch to electric vehicles and earlier thismonth started buying sharesin the U.S. listed Chinese electric automaker Xpeng Inc.\nHere are the other key trades on Wednesday:\n\nBought 104,489 shares — estimated to be worth $21.3 million — in Roku Inc on the dip. The stock closed 7.95% lower at $203.94 a share on Wednesday.\nBought 705,660 shares — estimated to be worth $13.7 million — in Robinhood Markets Inc. The stock closed 1.93% higher at $19.50 a share.","news_type":1,"symbols_score_info":{"ARKW":0.9,"ROKU":0.9,"TSLA":0.9,"HOOD":0.9,"ARKQ":0.9,"XPEV":0.9,"ARKK":0.9}},"isVote":1,"tweetType":1,"viewCount":3012,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690363086,"gmtCreate":1639636407181,"gmtModify":1639636408527,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Booking in yr end profits. Esp window dressing period for funds","listText":"Booking in yr end profits. Esp window dressing period for funds","text":"Booking in yr end profits. Esp window dressing period for funds","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/690363086","repostId":"1136577431","repostType":4,"isVote":1,"tweetType":1,"viewCount":2732,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607376014,"gmtCreate":1639493954044,"gmtModify":1639493964699,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Cham, solar stocks under sieged","listText":"Cham, solar stocks under sieged","text":"Cham, solar stocks under sieged","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607376014","repostId":"1171542547","repostType":2,"isVote":1,"tweetType":1,"viewCount":4736,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607358963,"gmtCreate":1639492818378,"gmtModify":1639492819875,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Right on the money!💰","listText":"Right on the money!💰","text":"Right on the money!💰","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607358963","repostId":"2191937232","repostType":2,"isVote":1,"tweetType":1,"viewCount":3490,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607353966,"gmtCreate":1639492721339,"gmtModify":1639492759672,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"✌ go for it!","listText":"✌ go for it!","text":"✌ go for it!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607353966","repostId":"1116496280","repostType":4,"isVote":1,"tweetType":1,"viewCount":2635,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607350975,"gmtCreate":1639492606402,"gmtModify":1639492724954,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Kids can travel sooon! 😂✌","listText":"Kids can travel sooon! 😂✌","text":"Kids can travel sooon! 😂✌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607350975","repostId":"1128237305","repostType":4,"repost":{"id":"1128237305","kind":"news","pubTimestamp":1639489011,"share":"https://www.laohu8.com/m/news/1128237305?lang=zh_CN&edition=full","pubTime":"2021-12-14 21:36","market":"us","language":"en","title":"Swiss to start Pfizer/BioNTech jab for children aged 5-11 in January<blockquote>瑞士将于1月开始为5-11岁儿童接种辉瑞/BioNTech疫苗</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1128237305","media":"Reuters","summary":"Swiss health authorities will start administering the COVID-19 vaccination from Pfizer and BioNTech ","content":"<p>Swiss health authorities will start administering the COVID-19 vaccination from Pfizer and BioNTech to children aged five to eleven from next month and recommend kids get two doses of the shot.</p><p><blockquote>瑞士卫生当局将从下个月开始为5至11岁的儿童接种辉瑞和BioNTech的新冠肺炎疫苗，并建议儿童接种两剂疫苗。</blockquote></p><p> \"If they wish, parents or legal guardians can have their child vaccinated on the basis of an individual assessment of the benefits and risks, as soon as the vaccination is available,\" the Federal Office of Public Health said on Tuesday.</p><p><blockquote>联邦公共卫生办公室周二表示：“如果父母或法定监护人愿意，一旦疫苗接种到位，他们可以根据对益处和风险的个人评估为孩子接种疫苗。”</blockquote></p><p> Supplies should be available from the beginning of January, it added.</p><p><blockquote>它补充说，供应应该从一月初开始供应。</blockquote></p><p> The recommendation particularly applies to children who already have serious health risks owing to a chronic condition. The vaccination is recommended as a priority for children who have close contact with people at especially high risk in the same household who cannot obtain protection from vaccination, for example because they have a weakened immune system, it said.</p><p><blockquote>该建议特别适用于已经因慢性病而面临严重健康风险的儿童。报告称，建议与同一家庭中风险特别高的人有密切接触的儿童优先接种疫苗，这些人无法获得疫苗接种保护，例如因为他们的免疫系统较弱。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Swiss to start Pfizer/BioNTech jab for children aged 5-11 in January<blockquote>瑞士将于1月开始为5-11岁儿童接种辉瑞/BioNTech疫苗</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSwiss to start Pfizer/BioNTech jab for children aged 5-11 in January<blockquote>瑞士将于1月开始为5-11岁儿童接种辉瑞/BioNTech疫苗</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-12-14 21:36</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Swiss health authorities will start administering the COVID-19 vaccination from Pfizer and BioNTech to children aged five to eleven from next month and recommend kids get two doses of the shot.</p><p><blockquote>瑞士卫生当局将从下个月开始为5至11岁的儿童接种辉瑞和BioNTech的新冠肺炎疫苗，并建议儿童接种两剂疫苗。</blockquote></p><p> \"If they wish, parents or legal guardians can have their child vaccinated on the basis of an individual assessment of the benefits and risks, as soon as the vaccination is available,\" the Federal Office of Public Health said on Tuesday.</p><p><blockquote>联邦公共卫生办公室周二表示：“如果父母或法定监护人愿意，一旦疫苗接种到位，他们可以根据对益处和风险的个人评估为孩子接种疫苗。”</blockquote></p><p> Supplies should be available from the beginning of January, it added.</p><p><blockquote>它补充说，供应应该从一月初开始供应。</blockquote></p><p> The recommendation particularly applies to children who already have serious health risks owing to a chronic condition. The vaccination is recommended as a priority for children who have close contact with people at especially high risk in the same household who cannot obtain protection from vaccination, for example because they have a weakened immune system, it said.</p><p><blockquote>该建议特别适用于已经因慢性病而面临严重健康风险的儿童。报告称，建议与同一家庭中风险特别高的人有密切接触的儿童优先接种疫苗，这些人无法获得疫苗接种保护，例如因为他们的免疫系统较弱。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/swiss-start-pfizer-biontech-jab-132632610.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/swiss-start-pfizer-biontech-jab-132632610.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128237305","content_text":"Swiss health authorities will start administering the COVID-19 vaccination from Pfizer and BioNTech to children aged five to eleven from next month and recommend kids get two doses of the shot.\n\"If they wish, parents or legal guardians can have their child vaccinated on the basis of an individual assessment of the benefits and risks, as soon as the vaccination is available,\" the Federal Office of Public Health said on Tuesday.\nSupplies should be available from the beginning of January, it added.\nThe recommendation particularly applies to children who already have serious health risks owing to a chronic condition. The vaccination is recommended as a priority for children who have close contact with people at especially high risk in the same household who cannot obtain protection from vaccination, for example because they have a weakened immune system, it said.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":884,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606932637,"gmtCreate":1638806915203,"gmtModify":1638806916383,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"ARM deal now hanging on a thread..","listText":"ARM deal now hanging on a thread..","text":"ARM deal now hanging on a thread..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606932637","repostId":"1162046477","repostType":4,"repost":{"id":"1162046477","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638784711,"share":"https://www.laohu8.com/m/news/1162046477?lang=zh_CN&edition=full","pubTime":"2021-12-06 17:58","market":"us","language":"en","title":"Nvidia stock dropped nearly 5% in premarket trading<blockquote>英伟达股价在盘前交易中下跌近5%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1162046477","media":"Tiger Newspress","summary":"Nvidia stock dropped nearly 5% in premarket trading.Nvidia’s plan to dominate chip design stymied by","content":"<p>Nvidia stock dropped nearly 5% in premarket trading.Nvidia’s plan to dominate chip design stymied by antitrust angst;CEO Jensen Huang sold 440000 shares last week,with a total value of about $140 million.</p><p><blockquote>英伟达股价在盘前交易中下跌近5%。英伟达主导芯片设计的计划因反垄断担忧而受阻；CEO黄仁勋上周出售了44万股，总价值约1.4亿美元。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/494eb32cb993b45b8f2677a4c48a9f94\" tg-width=\"852\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> When&nbsp;Nvidia Corp.&nbsp;announced plans to buy&nbsp;Arm Ltd.&nbsp;in September 2020, the deal was more than just the chip industry’s largest-ever acquisition -- the company said it would supercharge the technology found in everything from cars to smartphones.</p><p><blockquote>当英伟达公司(Nvidia Corp.)于2020年9月宣布计划收购Arm Ltd.时，这笔交易不仅仅是芯片行业有史以来最大的收购——该公司表示，这将增强从汽车到智能手机等各种产品的技术。</blockquote></p><p> Now, more than a year later, that audacious plan is in peril. The&nbsp;U.S. Federal Trade Commission&nbsp;sued to block the $40 billion purchase on Thursday, calling it a threat to semiconductor innovation. Arm customers have lined up against the transaction. And investors and analysts have written off the idea of it ever happening.</p><p><blockquote>现在，一年多过去了，这个大胆的计划岌岌可危。美国。美国联邦贸易委员会周四提起诉讼，要求阻止这笔400亿美元的收购，称其对半导体创新构成威胁。Arm的客户已经排队反对这笔交易。投资者和分析师已经放弃了这种情况会发生的想法。</blockquote></p><p> EU antitrust regulators have temporarily halted their investigation into Nvidia's&nbsp;bid for British chip designer ARM,as they await more information, according to a European Commission filing.</p><p><blockquote>根据欧盟委员会的一份文件，欧盟反垄断监管机构暂时停止了对英伟达收购英国芯片设计公司ARM的调查，因为他们正在等待更多信息。</blockquote></p><p> British antitrust agency CMA has also said it would open a full-scale investigation into the deal.</p><p><blockquote>英国反垄断机构CMA也表示将对该交易展开全面调查。</blockquote></p><p> Nvidia has vowed to fight on, but with regulatory scrutiny escalating around the world, the prospects are dim.</p><p><blockquote>英伟达发誓要继续战斗，但随着全球监管审查的升级，前景黯淡。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nvidia stock dropped nearly 5% in premarket trading<blockquote>英伟达股价在盘前交易中下跌近5%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNvidia stock dropped nearly 5% in premarket trading<blockquote>英伟达股价在盘前交易中下跌近5%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-06 17:58</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Nvidia stock dropped nearly 5% in premarket trading.Nvidia’s plan to dominate chip design stymied by antitrust angst;CEO Jensen Huang sold 440000 shares last week,with a total value of about $140 million.</p><p><blockquote>英伟达股价在盘前交易中下跌近5%。英伟达主导芯片设计的计划因反垄断担忧而受阻；CEO黄仁勋上周出售了44万股，总价值约1.4亿美元。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/494eb32cb993b45b8f2677a4c48a9f94\" tg-width=\"852\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> When&nbsp;Nvidia Corp.&nbsp;announced plans to buy&nbsp;Arm Ltd.&nbsp;in September 2020, the deal was more than just the chip industry’s largest-ever acquisition -- the company said it would supercharge the technology found in everything from cars to smartphones.</p><p><blockquote>当英伟达公司(Nvidia Corp.)于2020年9月宣布计划收购Arm Ltd.时，这笔交易不仅仅是芯片行业有史以来最大的收购——该公司表示，这将增强从汽车到智能手机等各种产品的技术。</blockquote></p><p> Now, more than a year later, that audacious plan is in peril. The&nbsp;U.S. Federal Trade Commission&nbsp;sued to block the $40 billion purchase on Thursday, calling it a threat to semiconductor innovation. Arm customers have lined up against the transaction. And investors and analysts have written off the idea of it ever happening.</p><p><blockquote>现在，一年多过去了，这个大胆的计划岌岌可危。美国。美国联邦贸易委员会周四提起诉讼，要求阻止这笔400亿美元的收购，称其对半导体创新构成威胁。Arm的客户已经排队反对这笔交易。投资者和分析师已经放弃了这种情况会发生的想法。</blockquote></p><p> EU antitrust regulators have temporarily halted their investigation into Nvidia's&nbsp;bid for British chip designer ARM,as they await more information, according to a European Commission filing.</p><p><blockquote>根据欧盟委员会的一份文件，欧盟反垄断监管机构暂时停止了对英伟达收购英国芯片设计公司ARM的调查，因为他们正在等待更多信息。</blockquote></p><p> British antitrust agency CMA has also said it would open a full-scale investigation into the deal.</p><p><blockquote>英国反垄断机构CMA也表示将对该交易展开全面调查。</blockquote></p><p> Nvidia has vowed to fight on, but with regulatory scrutiny escalating around the world, the prospects are dim.</p><p><blockquote>英伟达发誓要继续战斗，但随着全球监管审查的升级，前景黯淡。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162046477","content_text":"Nvidia stock dropped nearly 5% in premarket trading.Nvidia’s plan to dominate chip design stymied by antitrust angst;CEO Jensen Huang sold 440000 shares last week,with a total value of about $140 million.\n\nWhen Nvidia Corp. announced plans to buy Arm Ltd. in September 2020, the deal was more than just the chip industry’s largest-ever acquisition -- the company said it would supercharge the technology found in everything from cars to smartphones.\nNow, more than a year later, that audacious plan is in peril. The U.S. Federal Trade Commission sued to block the $40 billion purchase on Thursday, calling it a threat to semiconductor innovation. Arm customers have lined up against the transaction. And investors and analysts have written off the idea of it ever happening.\nEU antitrust regulators have temporarily halted their investigation into Nvidia's bid for British chip designer ARM,as they await more information, according to a European Commission filing.\nBritish antitrust agency CMA has also said it would open a full-scale investigation into the deal.\nNvidia has vowed to fight on, but with regulatory scrutiny escalating around the world, the prospects are dim.","news_type":1,"symbols_score_info":{"NVDA":0.9}},"isVote":1,"tweetType":1,"viewCount":1147,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606936759,"gmtCreate":1638806864679,"gmtModify":1638806865801,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Cheap might become cheaper","listText":"Cheap might become cheaper","text":"Cheap might become cheaper","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606936759","repostId":"1191828969","repostType":4,"repost":{"id":"1191828969","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638792831,"share":"https://www.laohu8.com/m/news/1191828969?lang=zh_CN&edition=full","pubTime":"2021-12-06 20:13","market":"us","language":"en","title":"Grab shares slid more than 4% in premarket trading<blockquote>Grab股价在盘前交易中下跌超过4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1191828969","media":"Tiger Newspress","summary":"Grab shares slid more than 4% in premarket trading.The&nbsp;Singapore ride-hailing firm&nbsp;went on sale last week.","content":"<p>Grab shares slid more than 4% in premarket trading.The&nbsp;Singapore ride-hailing firm&nbsp;went on sale last week.</p><p><blockquote>Grab股价在盘前交易中下跌超过4%。这家新加坡网约车公司上周开始出售。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/8de30b544b65a645e7a91a37bfb8d8f8\" tg-width=\"851\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab shares slid more than 4% in premarket trading<blockquote>Grab股价在盘前交易中下跌超过4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab shares slid more than 4% in premarket trading<blockquote>Grab股价在盘前交易中下跌超过4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-06 20:13</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Grab shares slid more than 4% in premarket trading.The&nbsp;Singapore ride-hailing firm&nbsp;went on sale last week.</p><p><blockquote>Grab股价在盘前交易中下跌超过4%。这家新加坡网约车公司上周开始出售。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/8de30b544b65a645e7a91a37bfb8d8f8\" tg-width=\"851\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191828969","content_text":"Grab shares slid more than 4% in premarket trading.The Singapore ride-hailing firm went on sale last week.","news_type":1,"symbols_score_info":{"GRAB":0.9}},"isVote":1,"tweetType":1,"viewCount":1180,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603131480,"gmtCreate":1638372108885,"gmtModify":1638373790753,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Peanuts to trillion dollar boys&nbsp; 😂😂💰💰💪","listText":"Peanuts to trillion dollar boys&nbsp; 😂😂💰💰💪","text":"Peanuts to trillion dollar boys 😂😂💰💰💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603131480","repostId":"1100878233","repostType":4,"isVote":1,"tweetType":1,"viewCount":1035,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603379930,"gmtCreate":1638370189886,"gmtModify":1638370192019,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"All this positive news, but unable to obtain that most elusive license.... so ironic.. 😂😂😂","listText":"All this positive news, but unable to obtain that most elusive license.... so ironic.. 😂😂😂","text":"All this positive news, but unable to obtain that most elusive license.... so ironic.. 😂😂😂","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/603379930","repostId":"1189400421","repostType":2,"isVote":1,"tweetType":1,"viewCount":1039,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600783599,"gmtCreate":1638197813016,"gmtModify":1638197835203,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Electric Dreams!! 🎶🎶🎵","listText":"Electric Dreams!! 🎶🎶🎵","text":"Electric Dreams!! 🎶🎶🎵","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/600783599","repostId":"1107575457","repostType":4,"repost":{"id":"1107575457","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638196680,"share":"https://www.laohu8.com/m/news/1107575457?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:38","market":"us","language":"en","title":"EV stocks surged in morning trading<blockquote>电动汽车股早盘飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1107575457","media":"Tiger Newspress","summary":"EV stocks surged in morning trading.Li Auto,Sono Group,Xpeng,Tesla,Rivian,Faraday Future,NIO and Arr","content":"<p>EV stocks surged in morning trading.Li Auto,Sono Group,Xpeng,Tesla,Rivian,Faraday Future,NIO&nbsp;and&nbsp;Arrival&nbsp;climbed between 2% and 10%.</p><p><blockquote>电动汽车股早盘飙升。理想汽车、索诺集团、小鹏汽车、特斯拉、Rivian、法拉第未来、蔚来和Arrival上涨2%至10%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b1d0af11193c5af65acbbf62d546a3b4\" tg-width=\"406\" tg-height=\"600\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks surged in morning trading<blockquote>电动汽车股早盘飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks surged in morning trading<blockquote>电动汽车股早盘飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:38</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>EV stocks surged in morning trading.Li Auto,Sono Group,Xpeng,Tesla,Rivian,Faraday Future,NIO&nbsp;and&nbsp;Arrival&nbsp;climbed between 2% and 10%.</p><p><blockquote>电动汽车股早盘飙升。理想汽车、索诺集团、小鹏汽车、特斯拉、Rivian、法拉第未来、蔚来和Arrival上涨2%至10%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b1d0af11193c5af65acbbf62d546a3b4\" tg-width=\"406\" tg-height=\"600\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","LI":"理想汽车","NIU":"小牛电动","RIVN":"Rivian Automotive, Inc.","FSR":"菲斯克","TSLA":"特斯拉","XPEV":"小鹏汽车","SEV":"Aptera Motors"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107575457","content_text":"EV stocks surged in morning trading.Li Auto,Sono Group,Xpeng,Tesla,Rivian,Faraday Future,NIO and Arrival climbed between 2% and 10%.","news_type":1,"symbols_score_info":{"TSLA":0.9,"FSR":0.9,"FFIE":0.9,"LI":0.9,"SEV":0.9,"NIO":0.9,"XPEV":0.9,"ARVL":0.9,"NIU":0.9,"RIVN":0.9}},"isVote":1,"tweetType":1,"viewCount":1084,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874839691,"gmtCreate":1637753502596,"gmtModify":1637754129808,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"When U pay peanuts, u get monkeys, well done PLTR, always pay your team well - and witness the shift! 😊🏆","listText":"When U pay peanuts, u get monkeys, well done PLTR, always pay your team well - and witness the shift! 😊🏆","text":"When U pay peanuts, u get monkeys, well done PLTR, always pay your team well - and witness the shift! 😊🏆","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874839691","repostId":"1127565646","repostType":4,"isVote":1,"tweetType":1,"viewCount":1213,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875523659,"gmtCreate":1637671543923,"gmtModify":1637671544586,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Production&nbsp;Capacity also requires some time to gain momentum. They think itz akin to fast food.. want cheap, want fast, want aplentiful. When demand suddenly fivefold, supply cannot keep up, what happens??&nbsp;","listText":"Production&nbsp;Capacity also requires some time to gain momentum. They think itz akin to fast food.. want cheap, want fast, want aplentiful. When demand suddenly fivefold, supply cannot keep up, what happens??&nbsp;","text":"Production Capacity also requires some time to gain momentum. They think itz akin to fast food.. want cheap, want fast, want aplentiful. When demand suddenly fivefold, supply cannot keep up, what happens??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875523659","repostId":"2185801154","repostType":4,"isVote":1,"tweetType":1,"viewCount":1062,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875043230,"gmtCreate":1637591927817,"gmtModify":1637591928448,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Time to protect our young tooo.;) Then travelling can truly take place.","listText":"Time to protect our young tooo.;) Then travelling can truly take place.","text":"Time to protect our young tooo.;) Then travelling can truly take place.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875043230","repostId":"2185787906","repostType":4,"isVote":1,"tweetType":1,"viewCount":924,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878524935,"gmtCreate":1637209735019,"gmtModify":1637209735566,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"The new guru has spoken!","listText":"The new guru has spoken!","text":"The new guru has spoken!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/878524935","repostId":"2184145859","repostType":2,"isVote":1,"tweetType":1,"viewCount":797,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":888637139,"gmtCreate":1631492740621,"gmtModify":1631884081107,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"New phone, new catalyst. Forget abt the lawsuit with Epic","listText":"New phone, new catalyst. Forget abt the lawsuit with Epic","text":"New phone, new catalyst. Forget abt the lawsuit with Epic","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/888637139","repostId":"2167630550","repostType":2,"isVote":1,"tweetType":1,"viewCount":864,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896278540,"gmtCreate":1628588969280,"gmtModify":1631888876154,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"1 dosage 100 mcg versus 30mcg from pfizer","listText":"1 dosage 100 mcg versus 30mcg from pfizer","text":"1 dosage 100 mcg versus 30mcg from pfizer","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/896278540","repostId":"1122891084","repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://www.laohu8.com/m/news/1122891084?lang=zh_CN&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠疫苗可能比辉瑞更好对抗德尔塔变异毒株；突破性案例随着时间的推移而增加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">莫德纳公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项尚未经过同行评审的研究包括了梅奥诊所卫生系统的50,000多名患者。</li><li>研究人员发现，Moderna的Covid-19疫苗的效力从2021年初的86%降至7月份（当时德尔塔变异毒株占主导地位）的76%。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在预防Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要进行Moderna加强注射。</li><li>在另一项研究中，安大略省的老年疗养院居民在注射Moderna疫苗后产生了比辉瑞/BioNTech疫苗后更强的免疫反应——特别是针对变异体。</li><li>辉瑞发言人表示：“我们仍然认为……在全面接种疫苗后的6至12个月内，可能需要第三剂加强剂，以保持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性新冠肺炎的几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，该研究包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测呈阳性的几率较高。</li><li>在60岁以上的患者中，自第二次注射后146天，检测呈阳性的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”以色列Leumit Health Services的合著者Eugene Merzon博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠疫苗可能比辉瑞更好对抗德尔塔变异毒株；突破性案例随着时间的推移而增加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠疫苗可能比辉瑞更好对抗德尔塔变异毒株；突破性案例随着时间的推移而增加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-10 16:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">莫德纳公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项尚未经过同行评审的研究包括了梅奥诊所卫生系统的50,000多名患者。</li><li>研究人员发现，Moderna的Covid-19疫苗的效力从2021年初的86%降至7月份（当时德尔塔变异毒株占主导地位）的76%。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在预防Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要进行Moderna加强注射。</li><li>在另一项研究中，安大略省的老年疗养院居民在注射Moderna疫苗后产生了比辉瑞/BioNTech疫苗后更强的免疫反应——特别是针对变异体。</li><li>辉瑞发言人表示：“我们仍然认为……在全面接种疫苗后的6至12个月内，可能需要第三剂加强剂，以保持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性新冠肺炎的几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，该研究包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测呈阳性的几率较高。</li><li>在60岁以上的患者中，自第二次注射后146天，检测呈阳性的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”以色列Leumit Health Services的合著者Eugene Merzon博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":474,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896276265,"gmtCreate":1628589075357,"gmtModify":1631888876156,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Hakuna Matata","listText":"Hakuna Matata","text":"Hakuna Matata","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/896276265","repostId":"1132629182","repostType":4,"repost":{"id":"1132629182","kind":"news","pubTimestamp":1628575408,"share":"https://www.laohu8.com/m/news/1132629182?lang=zh_CN&edition=full","pubTime":"2021-08-10 14:03","market":"other","language":"en","title":"Crude Oil and Iron Ore Prices in Tailspin as Covid Continues Spreading<blockquote>随着新冠疫情持续蔓延，原油和铁矿石价格陷入混乱</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1132629182","media":"DailyFX","summary":"CRUDE OIL, IRON ORE, CHINA, DELTA VARIANT – TALKING POINTS\n\nCrude Oil prices fall as China downgrade","content":"<p><b>CRUDE OIL, IRON ORE, CHINA, DELTA VARIANT – TALKING POINTS</b></p><p><blockquote><b>原油、铁矿石、中国、德尔塔变异毒株-谈话要点</b></blockquote></p><p> <ul>  <li>Crude Oil prices&nbsp;fall as China downgrades stifle demand bets</li>  <li>Iron ore prices join drop on Covid-induced demand worries</li>  <li>Australia Covid lockdowns likely to drag on as cases surge</li> </ul> Mounting worries over the quickly spreading Delta Covid variant’s impact on the global economy solidified further this week after Goldman Sachs and JP Morgan Chase downgraded economic outlooks on China. Goldman sees third-quarter growth slowing to 2.3% from 5.8%. A rebound in the fourth quarter may transpire, however, but the full-year projection remains worse off as restrictions are seen hampering consumption in the Chinese economy. Nearly 100 locally sourced cases were reported on Monday, according to China’s National Health Commission.</p><p><blockquote><ul><li>中国降级抑制需求押注原油价格下跌</li><li>由于新冠疫情引发的需求担忧，铁矿石价格也随之下跌</li><li>随着病例激增，澳大利亚新冠疫情封锁可能会持续下去</li></ul>在高盛和摩根大通下调中国经济前景后，人们对快速传播的Delta Covid变种对全球经济影响的担忧本周进一步加剧。高盛预计第三季度增长率将从5.8%放缓至2.3%。然而，第四季度可能会出现反弹，但由于限制措施阻碍了中国经济的消费，全年预测仍然更糟。据中国国家卫生健康委员会称，周一报告了近100例本地病例。</blockquote></p><p> The downbeat outlook weighed on&nbsp;crude oil&nbsp;and iron ore prices, two major commodities that are particularly insightful to gauge demand in the world’s second-largest economy. Crude oil fell nearly 2% on Monday, while the global benchmark, Brent, sank just over half a percent. Meanwhile, iron ore prices added to recent losses, extending the monthly drop to almost 10%. Iron ore prices are highly reliant on Chinese demand, given it is the largest importer of the mineral ore.</p><p><blockquote>悲观的前景打压了原油和铁矿石价格，这两种主要大宗商品在衡量世界第二大经济体的需求方面尤其具有洞察力。原油周一下跌近2%，而全球基准布伦特原油下跌略高于0.5%。与此同时，铁矿石价格加剧了近期的跌幅，将月度跌幅扩大至近10%。鉴于中国是铁矿石的最大进口国，铁矿石价格高度依赖中国的需求。</blockquote></p><p> The drop in prices may help ease some inflation pressure in the economy. Beijing moved to release state reserves of certain commodities in recent months, including crude oil and iron ore, to cool rapid price increases. The PBOC has also taken a variety of measures to support monetary policy,&nbsp;including a reduction in reserve ratio rates&nbsp;to&nbsp;spur bank lending.&nbsp;Balancing the recovery against growing inflation threats will remain key for Chinese authorities.</p><p><blockquote>价格下跌可能有助于缓解经济中的一些通胀压力。最近几个月，中国政府释放了包括原油和铁矿石在内的某些大宗商品的国家储备，以冷却快速上涨的价格。中国人民银行还采取了多种措施支持货币政策，包括降低准备金率以刺激银行放贷。平衡经济复苏与日益加剧的通胀威胁仍将是中国当局的关键。</blockquote></p><p> Still, China saw inflation - via CPI - rise 1.0% in July, while producer prices climbed 9.0% in the same time frame. Rising producer prices sometimes translate into higher prices for consumers down the road if producers feel the need to pass on higher input costs to consumers. Meanwhile, lockdowns in Australia are likely to drag on after New South Wales (NSW) reported 356 new virus cases on Tuesday. Overall, the Delta variant’s spread is now having a tangible and visible impact on global sentiment, particularly denting growth-sensitive commodities like oil and iron ore.</p><p><blockquote>尽管如此，中国7月份通胀（CPI）仍上涨1.0%，而同期生产者价格上涨9.0%。如果生产者觉得有必要将更高的投入成本转嫁给消费者，生产者价格上涨有时会转化为消费者未来更高的价格。与此同时，在新南威尔士州（NSW）周二报告356例新病毒病例后，澳大利亚的封锁可能会持续下去。总体而言，德尔塔变异毒株的利差现在对全球情绪产生了切实可见的影响，特别是削弱了石油和铁矿石等对增长敏感的大宗商品。</blockquote></p><p> <h3><b>CRUDE OIL TECHNICAL OUTLOOK</b></h3> Crude oil’s technical posture has weakened substantially since reaching a multi-year high at 76.98 back in late July. Since then, prices have dropped over 10%. The 100-day Simple Moving Average (SMA) has also been breached this week. However, a trendline formed from the March low appears to be underpinning further losses. If prices pierce below the trendline, an extension lower may be likely. Alternatively, holding the trendline may see the preceding trend higher continue.</p><p><blockquote><h3><b>原油技术展望</b></h3>自7月底触及76.98的多年高点以来，原油技术面已大幅走弱。自那以后，价格下降了10%以上。100日简单移动平均线(SMA)本周也被突破。然而，从三月低点形成的趋势线似乎支撑了进一步的下跌。如果价格跌破趋势线，可能会进一步走低。或者，保持趋势线可能会看到之前的趋势继续走高。</blockquote></p><p> <b>CRUDE OIL DAILY CHART</b><img src=\"https://static.tigerbbs.com/96527b766dd3c544aeb986dfae47a88d\" tg-width=\"624\" tg-height=\"405\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p><p><blockquote><b>原油日线图</b></blockquote></p><p> Chart created with&nbsp;TradingView</p><p><blockquote>使用TradingView创建的图表</blockquote></p><p> <h3><b>IRON ORE TECHNICAL OUTLOOK</b></h3> Iron ore prices have seen a sharp drop over the last few weeks, with a slice through the 100- and 200-day Simple Moving Averages (SMAs). A trendline from October was also breached with ease. Prices are over 20% lower since June, and the 2021 yearly gain is in danger of being wiped out. The April low at 158.10 appears to be providing a layer of support. Below that, the 2021 low at 146.55 may be endangered. Bulls may need to recapture the 200-day SMA to regain a solid footing to push higher.</p><p><blockquote><h3><b>铁矿石技术展望</b></h3>过去几周，铁矿石价格大幅下跌，突破100日和200日简单移动平均线(SMA)。10月份的趋势线也被轻松突破。自6月以来，价格下跌了20%以上，2021年的年度涨幅有被抹去的危险。4月份低点158.10似乎提供了一层支撑。低于该水平，2021年低点146.55可能会受到威胁。多头可能需要重新夺回200日移动平均线，以重新获得坚实的基础来推高。</blockquote></p><p> <b>IRON ORE DAILY CHART</b><img src=\"https://static.tigerbbs.com/64f038b392feb7397b76582fe26a66a8\" tg-width=\"625\" tg-height=\"527\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p><p><blockquote><b>铁矿石日线图</b></blockquote></p><p> Chart created with&nbsp;TradingView</p><p><blockquote>使用TradingView创建的图表</blockquote></p><p></p>","source":"lsy1568971417606","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crude Oil and Iron Ore Prices in Tailspin as Covid Continues Spreading<blockquote>随着新冠疫情持续蔓延，原油和铁矿石价格陷入混乱</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrude Oil and Iron Ore Prices in Tailspin as Covid Continues Spreading<blockquote>随着新冠疫情持续蔓延，原油和铁矿石价格陷入混乱</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">DailyFX</strong><span class=\"h-time small\">2021-08-10 14:03</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>CRUDE OIL, IRON ORE, CHINA, DELTA VARIANT – TALKING POINTS</b></p><p><blockquote><b>原油、铁矿石、中国、德尔塔变异毒株-谈话要点</b></blockquote></p><p> <ul>  <li>Crude Oil prices&nbsp;fall as China downgrades stifle demand bets</li>  <li>Iron ore prices join drop on Covid-induced demand worries</li>  <li>Australia Covid lockdowns likely to drag on as cases surge</li> </ul> Mounting worries over the quickly spreading Delta Covid variant’s impact on the global economy solidified further this week after Goldman Sachs and JP Morgan Chase downgraded economic outlooks on China. Goldman sees third-quarter growth slowing to 2.3% from 5.8%. A rebound in the fourth quarter may transpire, however, but the full-year projection remains worse off as restrictions are seen hampering consumption in the Chinese economy. Nearly 100 locally sourced cases were reported on Monday, according to China’s National Health Commission.</p><p><blockquote><ul><li>中国降级抑制需求押注原油价格下跌</li><li>由于新冠疫情引发的需求担忧，铁矿石价格也随之下跌</li><li>随着病例激增，澳大利亚新冠疫情封锁可能会持续下去</li></ul>在高盛和摩根大通下调中国经济前景后，人们对快速传播的Delta Covid变种对全球经济影响的担忧本周进一步加剧。高盛预计第三季度增长率将从5.8%放缓至2.3%。然而，第四季度可能会出现反弹，但由于限制措施阻碍了中国经济的消费，全年预测仍然更糟。据中国国家卫生健康委员会称，周一报告了近100例本地病例。</blockquote></p><p> The downbeat outlook weighed on&nbsp;crude oil&nbsp;and iron ore prices, two major commodities that are particularly insightful to gauge demand in the world’s second-largest economy. Crude oil fell nearly 2% on Monday, while the global benchmark, Brent, sank just over half a percent. Meanwhile, iron ore prices added to recent losses, extending the monthly drop to almost 10%. Iron ore prices are highly reliant on Chinese demand, given it is the largest importer of the mineral ore.</p><p><blockquote>悲观的前景打压了原油和铁矿石价格，这两种主要大宗商品在衡量世界第二大经济体的需求方面尤其具有洞察力。原油周一下跌近2%，而全球基准布伦特原油下跌略高于0.5%。与此同时，铁矿石价格加剧了近期的跌幅，将月度跌幅扩大至近10%。鉴于中国是铁矿石的最大进口国，铁矿石价格高度依赖中国的需求。</blockquote></p><p> The drop in prices may help ease some inflation pressure in the economy. Beijing moved to release state reserves of certain commodities in recent months, including crude oil and iron ore, to cool rapid price increases. The PBOC has also taken a variety of measures to support monetary policy,&nbsp;including a reduction in reserve ratio rates&nbsp;to&nbsp;spur bank lending.&nbsp;Balancing the recovery against growing inflation threats will remain key for Chinese authorities.</p><p><blockquote>价格下跌可能有助于缓解经济中的一些通胀压力。最近几个月，中国政府释放了包括原油和铁矿石在内的某些大宗商品的国家储备，以冷却快速上涨的价格。中国人民银行还采取了多种措施支持货币政策，包括降低准备金率以刺激银行放贷。平衡经济复苏与日益加剧的通胀威胁仍将是中国当局的关键。</blockquote></p><p> Still, China saw inflation - via CPI - rise 1.0% in July, while producer prices climbed 9.0% in the same time frame. Rising producer prices sometimes translate into higher prices for consumers down the road if producers feel the need to pass on higher input costs to consumers. Meanwhile, lockdowns in Australia are likely to drag on after New South Wales (NSW) reported 356 new virus cases on Tuesday. Overall, the Delta variant’s spread is now having a tangible and visible impact on global sentiment, particularly denting growth-sensitive commodities like oil and iron ore.</p><p><blockquote>尽管如此，中国7月份通胀（CPI）仍上涨1.0%，而同期生产者价格上涨9.0%。如果生产者觉得有必要将更高的投入成本转嫁给消费者，生产者价格上涨有时会转化为消费者未来更高的价格。与此同时，在新南威尔士州（NSW）周二报告356例新病毒病例后，澳大利亚的封锁可能会持续下去。总体而言，德尔塔变异毒株的利差现在对全球情绪产生了切实可见的影响，特别是削弱了石油和铁矿石等对增长敏感的大宗商品。</blockquote></p><p> <h3><b>CRUDE OIL TECHNICAL OUTLOOK</b></h3> Crude oil’s technical posture has weakened substantially since reaching a multi-year high at 76.98 back in late July. Since then, prices have dropped over 10%. The 100-day Simple Moving Average (SMA) has also been breached this week. However, a trendline formed from the March low appears to be underpinning further losses. If prices pierce below the trendline, an extension lower may be likely. Alternatively, holding the trendline may see the preceding trend higher continue.</p><p><blockquote><h3><b>原油技术展望</b></h3>自7月底触及76.98的多年高点以来，原油技术面已大幅走弱。自那以后，价格下降了10%以上。100日简单移动平均线(SMA)本周也被突破。然而，从三月低点形成的趋势线似乎支撑了进一步的下跌。如果价格跌破趋势线，可能会进一步走低。或者，保持趋势线可能会看到之前的趋势继续走高。</blockquote></p><p> <b>CRUDE OIL DAILY CHART</b><img src=\"https://static.tigerbbs.com/96527b766dd3c544aeb986dfae47a88d\" tg-width=\"624\" tg-height=\"405\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p><p><blockquote><b>原油日线图</b></blockquote></p><p> Chart created with&nbsp;TradingView</p><p><blockquote>使用TradingView创建的图表</blockquote></p><p> <h3><b>IRON ORE TECHNICAL OUTLOOK</b></h3> Iron ore prices have seen a sharp drop over the last few weeks, with a slice through the 100- and 200-day Simple Moving Averages (SMAs). A trendline from October was also breached with ease. Prices are over 20% lower since June, and the 2021 yearly gain is in danger of being wiped out. The April low at 158.10 appears to be providing a layer of support. Below that, the 2021 low at 146.55 may be endangered. Bulls may need to recapture the 200-day SMA to regain a solid footing to push higher.</p><p><blockquote><h3><b>铁矿石技术展望</b></h3>过去几周，铁矿石价格大幅下跌，突破100日和200日简单移动平均线(SMA)。10月份的趋势线也被轻松突破。自6月以来，价格下跌了20%以上，2021年的年度涨幅有被抹去的危险。4月份低点158.10似乎提供了一层支撑。低于该水平，2021年低点146.55可能会受到威胁。多头可能需要重新夺回200日移动平均线，以重新获得坚实的基础来推高。</blockquote></p><p> <b>IRON ORE DAILY CHART</b><img src=\"https://static.tigerbbs.com/64f038b392feb7397b76582fe26a66a8\" tg-width=\"625\" tg-height=\"527\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p><p><blockquote><b>铁矿石日线图</b></blockquote></p><p> Chart created with&nbsp;TradingView</p><p><blockquote>使用TradingView创建的图表</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.dailyfx.com/forex/fundamental/daily_briefing/daily_pieces/commodities/2021/08/10/Crude-Oil-and-Iron-Ore-Prices-in-Tailspin-as-Covid-Seen-Damaging-Chinas-Growth.html\">DailyFX</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AXXDF":"Alderon Iron Ore Corp.","FEOVF":"Oceanic Iron Ore Corp."},"source_url":"https://www.dailyfx.com/forex/fundamental/daily_briefing/daily_pieces/commodities/2021/08/10/Crude-Oil-and-Iron-Ore-Prices-in-Tailspin-as-Covid-Seen-Damaging-Chinas-Growth.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132629182","content_text":"CRUDE OIL, IRON ORE, CHINA, DELTA VARIANT – TALKING POINTS\n\nCrude Oil prices fall as China downgrades stifle demand bets\nIron ore prices join drop on Covid-induced demand worries\nAustralia Covid lockdowns likely to drag on as cases surge\n\nMounting worries over the quickly spreading Delta Covid variant’s impact on the global economy solidified further this week after Goldman Sachs and JP Morgan Chase downgraded economic outlooks on China. Goldman sees third-quarter growth slowing to 2.3% from 5.8%. A rebound in the fourth quarter may transpire, however, but the full-year projection remains worse off as restrictions are seen hampering consumption in the Chinese economy. Nearly 100 locally sourced cases were reported on Monday, according to China’s National Health Commission.\nThe downbeat outlook weighed on crude oil and iron ore prices, two major commodities that are particularly insightful to gauge demand in the world’s second-largest economy. Crude oil fell nearly 2% on Monday, while the global benchmark, Brent, sank just over half a percent. Meanwhile, iron ore prices added to recent losses, extending the monthly drop to almost 10%. Iron ore prices are highly reliant on Chinese demand, given it is the largest importer of the mineral ore.\nThe drop in prices may help ease some inflation pressure in the economy. Beijing moved to release state reserves of certain commodities in recent months, including crude oil and iron ore, to cool rapid price increases. The PBOC has also taken a variety of measures to support monetary policy, including a reduction in reserve ratio rates to spur bank lending. Balancing the recovery against growing inflation threats will remain key for Chinese authorities.\nStill, China saw inflation - via CPI - rise 1.0% in July, while producer prices climbed 9.0% in the same time frame. Rising producer prices sometimes translate into higher prices for consumers down the road if producers feel the need to pass on higher input costs to consumers. Meanwhile, lockdowns in Australia are likely to drag on after New South Wales (NSW) reported 356 new virus cases on Tuesday. Overall, the Delta variant’s spread is now having a tangible and visible impact on global sentiment, particularly denting growth-sensitive commodities like oil and iron ore.\nCRUDE OIL TECHNICAL OUTLOOK\nCrude oil’s technical posture has weakened substantially since reaching a multi-year high at 76.98 back in late July. Since then, prices have dropped over 10%. The 100-day Simple Moving Average (SMA) has also been breached this week. However, a trendline formed from the March low appears to be underpinning further losses. If prices pierce below the trendline, an extension lower may be likely. Alternatively, holding the trendline may see the preceding trend higher continue.\nCRUDE OIL DAILY CHART\nChart created with TradingView\nIRON ORE TECHNICAL OUTLOOK\nIron ore prices have seen a sharp drop over the last few weeks, with a slice through the 100- and 200-day Simple Moving Averages (SMAs). A trendline from October was also breached with ease. Prices are over 20% lower since June, and the 2021 yearly gain is in danger of being wiped out. The April low at 158.10 appears to be providing a layer of support. Below that, the 2021 low at 146.55 may be endangered. Bulls may need to recapture the 200-day SMA to regain a solid footing to push higher.\nIRON ORE DAILY CHART\nChart created with TradingView","news_type":1,"symbols_score_info":{"UKOILmain":0.9,"BZmain":0.9,"AXXDF":0.9,"FEOVF":0.9}},"isVote":1,"tweetType":1,"viewCount":280,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880321692,"gmtCreate":1631021704616,"gmtModify":1631885186433,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Next milestone set, probably a question of not \"if\" but&nbsp;\"when\" (\",)","listText":"Next milestone set, probably a question of not \"if\" but&nbsp;\"when\" (\",)","text":"Next milestone set, probably a question of not \"if\" but \"when\" (\",)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/880321692","repostId":"1170276114","repostType":2,"isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":603379930,"gmtCreate":1638370189886,"gmtModify":1638370192019,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"All this positive news, but unable to obtain that most elusive license.... so ironic.. 😂😂😂","listText":"All this positive news, but unable to obtain that most elusive license.... so ironic.. 😂😂😂","text":"All this positive news, but unable to obtain that most elusive license.... so ironic.. 😂😂😂","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/603379930","repostId":"1189400421","repostType":2,"isVote":1,"tweetType":1,"viewCount":1039,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600783599,"gmtCreate":1638197813016,"gmtModify":1638197835203,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Electric Dreams!! 🎶🎶🎵","listText":"Electric Dreams!! 🎶🎶🎵","text":"Electric Dreams!! 🎶🎶🎵","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/600783599","repostId":"1107575457","repostType":4,"repost":{"id":"1107575457","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638196680,"share":"https://www.laohu8.com/m/news/1107575457?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:38","market":"us","language":"en","title":"EV stocks surged in morning trading<blockquote>电动汽车股早盘飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1107575457","media":"Tiger Newspress","summary":"EV stocks surged in morning trading.Li Auto,Sono Group,Xpeng,Tesla,Rivian,Faraday Future,NIO and Arr","content":"<p>EV stocks surged in morning trading.Li Auto,Sono Group,Xpeng,Tesla,Rivian,Faraday Future,NIO&nbsp;and&nbsp;Arrival&nbsp;climbed between 2% and 10%.</p><p><blockquote>电动汽车股早盘飙升。理想汽车、索诺集团、小鹏汽车、特斯拉、Rivian、法拉第未来、蔚来和Arrival上涨2%至10%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b1d0af11193c5af65acbbf62d546a3b4\" tg-width=\"406\" tg-height=\"600\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks surged in morning trading<blockquote>电动汽车股早盘飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks surged in morning trading<blockquote>电动汽车股早盘飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:38</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>EV stocks surged in morning trading.Li Auto,Sono Group,Xpeng,Tesla,Rivian,Faraday Future,NIO&nbsp;and&nbsp;Arrival&nbsp;climbed between 2% and 10%.</p><p><blockquote>电动汽车股早盘飙升。理想汽车、索诺集团、小鹏汽车、特斯拉、Rivian、法拉第未来、蔚来和Arrival上涨2%至10%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b1d0af11193c5af65acbbf62d546a3b4\" tg-width=\"406\" tg-height=\"600\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","LI":"理想汽车","NIU":"小牛电动","RIVN":"Rivian Automotive, Inc.","FSR":"菲斯克","TSLA":"特斯拉","XPEV":"小鹏汽车","SEV":"Aptera Motors"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107575457","content_text":"EV stocks surged in morning trading.Li Auto,Sono Group,Xpeng,Tesla,Rivian,Faraday Future,NIO and Arrival climbed between 2% and 10%.","news_type":1,"symbols_score_info":{"TSLA":0.9,"FSR":0.9,"FFIE":0.9,"LI":0.9,"SEV":0.9,"NIO":0.9,"XPEV":0.9,"ARVL":0.9,"NIU":0.9,"RIVN":0.9}},"isVote":1,"tweetType":1,"viewCount":1084,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873916952,"gmtCreate":1636839774214,"gmtModify":1636839774718,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Showing the way to beat the virus 🙏✌👍🍯","listText":"Showing the way to beat the virus 🙏✌👍🍯","text":"Showing the way to beat the virus 🙏✌👍🍯","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873916952","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=zh_CN&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-13 11:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":556,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":814077352,"gmtCreate":1630735251276,"gmtModify":1631885186445,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"Not a Major threat (yet), but do stay alert of the unknowns","listText":"Not a Major threat (yet), but do stay alert of the unknowns","text":"Not a Major threat (yet), but do stay alert of the unknowns","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/814077352","repostId":"2164877249","repostType":2,"isVote":1,"tweetType":1,"viewCount":847,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801680528,"gmtCreate":1627514709564,"gmtModify":1631883895858,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"The connection to the IOT and electrification of road Infra and EV (cars to talk to one another, on traffic jams etc) means chips' demand will only increase than decrease!","listText":"The connection to the IOT and electrification of road Infra and EV (cars to talk to one another, on traffic jams etc) means chips' demand will only increase than decrease!","text":"The connection to the IOT and electrification of road Infra and EV (cars to talk to one another, on traffic jams etc) means chips' demand will only increase than decrease!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/801680528","repostId":"1191373397","repostType":4,"isVote":1,"tweetType":1,"viewCount":409,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148932107,"gmtCreate":1625912486709,"gmtModify":1633936147681,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579482809178950","idStr":"3579482809178950"},"themes":[],"htmlText":"At a crossroad for Tesla in PRC","listText":"At a crossroad for Tesla in PRC","text":"At a crossroad for Tesla in PRC","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/148932107","repostId":"1158342403","repostType":4,"repost":{"id":"1158342403","kind":"news","pubTimestamp":1625840608,"share":"https://www.laohu8.com/m/news/1158342403?lang=zh_CN&edition=full","pubTime":"2021-07-09 22:23","market":"us","language":"en","title":"Tesla Shares Form Death Cross, Portending Further Declines<blockquote>特斯拉股价形成死亡交叉，预示着进一步下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1158342403","media":"Bloomberg","summary":"(Bloomberg) -- Tesla Inc. shares formed a trading pattern Friday that is closely watched by traders ","content":"<p><img src=\"https://static.tigerbbs.com/bb51ddaee6b764108c6a043b0481069f\" tg-width=\"704\" tg-height=\"396\" referrerpolicy=\"no-referrer\">(Bloomberg) -- Tesla Inc. shares formed a trading pattern Friday that is closely watched by traders as it often precedes further losses for the stock.</p><p><blockquote>（彭博社）——特斯拉公司股价周五形成了一种交易模式，受到交易员的密切关注，因为这种模式往往先于该股进一步下跌。</blockquote></p><p> The short-term average price for the stock fell below the long-term average, forming a so-called death cross. Shares of the electric vehicle maker have been on a rough ride already this year, falling 8%, even as the broader market rose nearly 16%.</p><p><blockquote>该股的短期平均价格跌破长期平均价格，形成所谓的死亡交叉。尽管大盘上涨了近16%，但这家电动汽车制造商的股价今年已经经历了艰难时期，下跌了8%。</blockquote></p><p> The decline reflects growing investor concern about competition from traditional carmakers that are pushing aggressively into the EV race, as well as the company’s future growth trajectory in China, which is among the world’s biggest markets for automobiles. On Thursday, Tesla unveiled a significantly cheaper version of its Model Y car in the country, even as its China deliveries dropped last month.</p><p><blockquote>这一下降反映出投资者越来越担心来自积极进军电动汽车竞赛的传统汽车制造商的竞争，以及该公司在中国（全球最大的汽车市场之一）的未来增长轨迹。周四，特斯拉在中国推出了一款便宜得多的Model Y汽车，尽管上个月其在华交付量有所下降。</blockquote></p><p> The last time Tesla shares formed this trading pattern was in February 2019, and it preceded a more than 40% decline in the share price within 65 days, to $35.79 from $63.98.</p><p><blockquote>特斯拉股价上一次形成这种交易模式是在2019年2月，此前股价在65天内下跌了40%以上，从63.98美元跌至35.79美元。</blockquote></p><p> Tesla shares dropped as much as 1.2% on Friday in New York. Shares of smaller EV startups also languished, with Workhorse Group Inc. and XPeng Inc. among the biggest decliners in the group.</p><p><blockquote>周五，特斯拉股价在纽约下跌1.2%。规模较小的电动汽车初创公司的股价也表现不佳，其中Workhorse Group Inc.和小鹏汽车是该集团中跌幅最大的公司之一。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Shares Form Death Cross, Portending Further Declines<blockquote>特斯拉股价形成死亡交叉，预示着进一步下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Shares Form Death Cross, Portending Further Declines<blockquote>特斯拉股价形成死亡交叉，预示着进一步下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-07-09 22:23</span>\n</p>\n</h4>\n</header>\n<article>\n<p><img src=\"https://static.tigerbbs.com/bb51ddaee6b764108c6a043b0481069f\" tg-width=\"704\" tg-height=\"396\" referrerpolicy=\"no-referrer\">(Bloomberg) -- Tesla Inc. shares formed a trading pattern Friday that is closely watched by traders as it often precedes further losses for the stock.</p><p><blockquote>（彭博社）——特斯拉公司股价周五形成了一种交易模式，受到交易员的密切关注，因为这种模式往往先于该股进一步下跌。</blockquote></p><p> The short-term average price for the stock fell below the long-term average, forming a so-called death cross. Shares of the electric vehicle maker have been on a rough ride already this year, falling 8%, even as the broader market rose nearly 16%.</p><p><blockquote>该股的短期平均价格跌破长期平均价格，形成所谓的死亡交叉。尽管大盘上涨了近16%，但这家电动汽车制造商的股价今年已经经历了艰难时期，下跌了8%。</blockquote></p><p> The decline reflects growing investor concern about competition from traditional carmakers that are pushing aggressively into the EV race, as well as the company’s future growth trajectory in China, which is among the world’s biggest markets for automobiles. On Thursday, Tesla unveiled a significantly cheaper version of its Model Y car in the country, even as its China deliveries dropped last month.</p><p><blockquote>这一下降反映出投资者越来越担心来自积极进军电动汽车竞赛的传统汽车制造商的竞争，以及该公司在中国（全球最大的汽车市场之一）的未来增长轨迹。周四，特斯拉在中国推出了一款便宜得多的Model Y汽车，尽管上个月其在华交付量有所下降。</blockquote></p><p> The last time Tesla shares formed this trading pattern was in February 2019, and it preceded a more than 40% decline in the share price within 65 days, to $35.79 from $63.98.</p><p><blockquote>特斯拉股价上一次形成这种交易模式是在2019年2月，此前股价在65天内下跌了40%以上，从63.98美元跌至35.79美元。</blockquote></p><p> Tesla shares dropped as much as 1.2% on Friday in New York. Shares of smaller EV startups also languished, with Workhorse Group Inc. and XPeng Inc. among the biggest decliners in the group.</p><p><blockquote>周五，特斯拉股价在纽约下跌1.2%。规模较小的电动汽车初创公司的股价也表现不佳，其中Workhorse Group Inc.和小鹏汽车是该集团中跌幅最大的公司之一。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/tesla-shares-form-death-cross-140046201.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://finance.yahoo.com/news/tesla-shares-form-death-cross-140046201.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158342403","content_text":"(Bloomberg) -- Tesla Inc. shares formed a trading pattern Friday that is closely watched by traders as it often precedes further losses for the stock.\nThe short-term average price for the stock fell below the long-term average, forming a so-called death cross. Shares of the electric vehicle maker have been on a rough ride already this year, falling 8%, even as the broader market rose nearly 16%.\nThe decline reflects growing investor concern about competition from traditional carmakers that are pushing aggressively into the EV race, as well as the company’s future growth trajectory in China, which is among the world’s biggest markets for automobiles. On Thursday, Tesla unveiled a significantly cheaper version of its Model Y car in the country, even as its China deliveries dropped last month.\nThe last time Tesla shares formed this trading pattern was in February 2019, and it preceded a more than 40% decline in the share price within 65 days, to $35.79 from $63.98.\nTesla shares dropped as much as 1.2% on Friday in New York. Shares of smaller EV startups also languished, with Workhorse Group Inc. and XPeng Inc. among the biggest decliners in the group.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":523,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}